NCT00949923

Green Tea in Breast Cancer Patients

Completed NA Last updated 30 March 2018

What this trial tests

NA trial testing tea capsule in Incident Breast Cancer in 41 participants. Completed in 6 June 2016.

Timeline

7 May 2008

Primary endpoint
14 December 2010

6 June 2016

Quick facts

Lead sponsor	University of Southern California
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	41
Start date	7 May 2008
Primary completion	14 December 2010
Estimated completion	6 June 2016
Sites	1 location across United States

Drugs / interventions tested

• tea capsule

Conditions studied

• Incident Breast Cancer — all drugs for Incident Breast Cancer →

Sponsor

University of Southern California

Who can join

18 and older, female only, with Incident Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prognostic factors for breast cancer beyond stage at diagnosis and tumor characteristics have not been well studied. Of special interest are lifestyle factors that can be modified by women after diagnosis to increase disease-free survival. Green tea is rich in polyphenols consisting primarily of epicatechins, epigallocatechin, epicatechin gallate, and epigallocatechin gallate (EGCG). The investigators hypothesize that there will be a reduction in proliferation and/or an increase in apoptosis in association with short-term EGCG treatment.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.
   Vernieri C, Casola S, Foiani M, Pietrantonio F, et al · · 2016 · cited 155× · PMID 27872127 · DOI 10.1158/2159-8290.cd-16-0615
2. Pharmacokinetic and chemoprevention studies on tea in humans.
   Chow HH, Hakim IA. · · 2011 · cited 91× · PMID 21624470 · DOI 10.1016/j.phrs.2011.05.007
3. Regulation of microRNAs by natural agents: new strategies in cancer therapies.
   Phuah NH, Nagoor NH. · · 2014 · cited 90× · PMID 25254214 · DOI 10.1155/2014/804510
4. Role of dietary bioactive natural products in estrogen receptor-positive breast cancer.
   Bak MJ, Das Gupta S, Wahler J, Suh N. · · 2016 · cited 56× · PMID 27016037 · DOI 10.1016/j.semcancer.2016.03.001
5. Targeting the hallmarks of cancer with therapy-induced endoplasmic reticulum (ER) stress.
   Garg AD, Maes H, van Vliet AR, Agostinis P. · · 2015 · cited 55× · PMID 27308392 · DOI 10.4161/23723556.2014.975089
6. Antioxidants for the Treatment of Breast Cancer: Are We There Yet?
   Griñan-Lison C, Blaya-Cánovas JL, López-Tejada A, Ávalos-Moreno M, et al · · 2021 · cited 43× · PMID 33572626 · DOI 10.3390/antiox10020205
7. Therapeutic Implications of Dietary Polyphenols-Loaded Nanoemulsions in Cancer Therapy.
   Tomar R, Das SS, Balaga VKR, Tambe S, et al · · 2024 · cited 10× · PMID 38525971 · DOI 10.1021/acsabm.3c01205
8. Dietary Polyphenols against Oxidative Stress in Head and Neck Cancer: What's New, What's Next.
   Ballini A, Zhurakivska K, Troiano G, Lo Muzio L, et al · · 2024 · cited 7× · PMID 38169656 · DOI 10.7150/jca.90545